What is Ande?
Founded in 2004, ANDE is globally recognized as the pioneer in Rapid DNA technology, dedicated to enhancing safety through its advanced solutions. The company's technology is instrumental in a variety of applications, including law enforcement investigations, military operations, and disaster victim identification, serving clients both domestically and internationally. ANDE's system has achieved critical approvals from the FBI's NDIS for generating DNA IDs from cheek swabs and from the Department of Defense for processing a wide array of forensic and disaster-related samples. With offices in Waltham, MA; Longmont, CO; and Washington, D.C., ANDE is strategically positioned to deploy its life-saving technology.
How much funding has Ande raised?
Ande has raised a total of $18M across 2 funding rounds:
Private Equity
$16M
Debt
$2M
Private Equity (2017): $16M, investors not publicly disclosed
Debt (2020): $2M led by PPP
Key Investors in Ande
PPP
Public-Private Partnership
What's next for Ande?
The substantial enterprise-level funding and recent strategic investment signal a pivotal phase for ANDE, likely focused on expanding its market reach and accelerating the deployment of its Rapid DNA technology. This capital infusion is expected to fuel further research and development, enhance manufacturing capabilities, and strengthen its global sales and support infrastructure. As ANDE continues to solidify its position as a leader in forensic and identification solutions, this backing will be crucial for capitalizing on emerging opportunities and addressing the growing demand for rapid, accurate DNA analysis in critical security and humanitarian applications. The company's strategic focus will likely involve deepening its partnerships with law enforcement and government agencies, further embedding its technology into essential identification workflows.
See full Ande company page
